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Abstract
Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower
extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the
patient’s general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to
best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society
for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either
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endovascular or surgical revascularisation, maintaining long-term patency is often challenging. Early and late procedural
complications, but also local and remote recurrences frequently lead to revascularisation failure. The rationale for
surveillance is to propose the accurate implementation of preventive strategies to avoid other cardiovascular events
and disease progression and avoid recurrence of symptoms and the need for redo revascularisation. Combined with
vascular history and physical examination, duplex ultrasound scanning is the pivotal imaging technique for identifying
revascularisation failures. Other non-invasive examinations (ankle and toe brachial index, computed tomography scan,
magnetic resonance imaging) at regular intervals can optimise surveillance in specific settings. Currently, optimal
revascularisation surveillance programmes are not well defined and systematic reviews addressing long-term results
after revascularisation are lacking. We have systematically reviewed the literature addressing follow-up after revascular-
isation and we propose this consensus document as a complement to the recent guidelines for optimal surveillance of
revascularised patients beyond the perioperative period.
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Introduction
Peripheral arterial diseases encompass diﬀerent clinical
presentations, from cerebrovascular disease to lower
extremity artery disease (LEAD), from subclinical to
disabling symptoms and events.1,2 The 2017 European
Society of Cardiology (ESC) guidelines in collaboration
with the European Society for Vascular Surgery (ESVS)
have addressed the indications for revascularisation.3
In 2008, over 98,000 endovascular procedures and
over 86,000 surgical revascularisations were performed
for lower limb arterial disease in Germany alone,4 illus-
trating the burden of peripheral revascularisation inter-
ventions in Europe.
Maintaining long-term patency after revascularisa-
tion is often challenging. Early and late procedural
complications, but also target and non-target lesion
recurrences, frequently lead to revascularisation failure.
Henceforth, the rationale for surveillance is:
. to detect and treat imminent revascularisation
failure before patency loss and thereby to prevent
complications and redo revascularisations.
. to implement optimal preventive strategies for disease
progression and avoid other cardiovascular events.
This consensus document combines a systematic
literature review on the follow-up beyond the peri-
operative period and experts’ inputs to standardise
the follow-up of revascularised patients. It is a comple-
ment to the recent guidelines elaborated through the
collaboration of the ESC and the ESVS.3
The evidence supporting systematic surveillance
after revascularisation is poor, largely due to a lack of
good evidence. In this situation, the opinion of the
authors of this interdisciplinary consensus document
is that the proposed surveillance strategy may be
appropriate while awaiting better quality data to be
acquired. Importantly, the regular follow-up of revas-
cularised patients does not systematically imply the use
of imaging techniques. Clinical assessment and imple-
mentation of preventive measures remain the pillars of
the follow-up programme. These could either be per-
formed by general practitioners or cardiovascular spe-
cialists (cardiologists, vascular physicians or vascular
surgeons) according to the management of patients in
diﬀerent countries. The recommendations here apply
irrespective of the healthcare systems.
General aspects
Complications after revascularisation
Revascularisation success is multifactorial, starting with
the indication of the procedure, the quality of the pre-
operative assessment and the intervention itself. The
postoperative events are timedependent: the rates of pro-
cedure-speciﬁc adverse events decrease over time while
disease-speciﬁc events are predominant thereafter. The
postoperative complications are usually divided into
early (<1 month), mid (1–12 months) and long-term
(>12 months). This paper focuses on the surveillance
needed to prevent mid and long-term adverse events.
During these periods the events are either local, speciﬁc
to the revascularised organ/limb (e.g. bypass throm-
bosis), or general (e.g. myocardial infarction). Follow-
up should therefore include general cardiovascular pre-
vention, surveillanceandcarebyamultidisciplinary team
(Table 1). In the case of repetitive thrombosis after revas-
cularisation, drug adherence, response to antithrombotic
drugs and coagulation disorders should be investigated.
Mid-term complications (1–12 months). Acute thrombosis
of the revascularised site despite antithrombotic
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therapy is a major complication after revascularisation.
Embolism to arteries distal to the revascularised site
can also cause ischaemic symptoms.
Restenosis may occur several months after surgical
or endovascular revascularisation.5–7
The primary pathway is intimal hyperplasia, with
luminal area loss despite geometric remodelling.
Intimal hyperplasia lesions are classically detected
from a few weeks to 2 years after intervention.8
Wall shear stress and wall tension stress are con-
sidered as initiators and modulators of intimal hyper-
plasia.9 Vascular reconstructions such as vein bypass
grafts and stented diseased arteries frequently induce a
disordered ﬂow pattern with low wall shear stress
which accelerates intimal hyperplasia.10 At suture
lines the process is also induced by diﬀerential compli-
ance between the prosthesis and the grafted artery.
Long-term complications (>12 months). Complications dir-
ectly related to revascularisation can still occur after
one year, but are progressively dominated by disease
progression and general cardiovascular events, both
highly dependent on the quality of cardiovascular pre-
vention. The optimal medical management of patients
with peripheral arterial diseases is detailed in the ESC
and ESVS guidelines.3
Patients’ follow-up
Clinical follow-up. The clinical follow-up includes the
assessment of any symptom or physical sign suggesting
revascularisation failure, or any other cardiovascular
condition, as well as ensuring optimal cardiovascular
prevention and drug adherence (Table 1). The compli-
ance to secondary prevention and exercise training, as
well as awareness of revascularisation failure symptoms
needing immediate contact with vascular specialists, are
important factors of long-term success.11–14
Imaging techniques. Because it is non-invasive and widely
available, duplex ultrasound (DUS) performed by
experienced operators is usually the ﬁrst-line technique.
It can be repeated over time to detect subclinical
abnormalities or verify whether symptoms are related
to revascularisation failure and/or disease progression.
Other functional tests such as ankle brachial index
(ABI) or toe brachial index (TBI) can optimise
the surveillance of lower limbs. Computed tomog-
raphy angiography (CTA) and magnetic resonance angi-
ography (MRA) are mostly limited to the conﬁrmation
and investigation of DUS ﬁndings but can be performed
straight away in urgent cases. Radiation (CTA), contrast
agent nephrotoxicity (CTA, but also MRA) and allergies
should always be considered.
Extracranial carotid artery disease
Mid and long-term outcome after revascularisation
Carotid endarterectomy. In a meta-analysis of 11 rando-
mised clinical trials (RCTs) including 4249 patients
with follow-up over a mean of 47 months, the rate of
Table 1. Checklist of items to be regularly assessed during the
mid and long-term follow-up visits.
Cardiovascular prevention
 Tobacco smoking status
 If smoking history: is cessation achieved?
If yes: be supportive
If not: propose specific intervention and follow-up,
refer to
smoking cessation programmes if available
 Hypertension
 Check brachial blood pressure bilaterally, at least annually:
blood pressure should be <140/90mmHg with the target
of 130/80mmHg if tolerated
 If treated hypertension:
Check diet and drug adherence
Check for other target organ damage (e.g. renal disease)
 If high blood pressure during a visit:
Reassess (ambulatory)
Refer to hypertension specialists
 Diabetes
 Check fasting glucose at least annually
 If diabetes: check glycated haemoglobin (optimally
HbA1c< 7%)
 Check treatment and diet adherence
 If newly detected or poorly controlled diabetes: refer to
diabetes specialist
 Cholesterol
 Check lipid levels at least annually: low-density lipoprotein
cholesterol should be <1.8mmol/l (70mg/dL) or
decreased at least by 50% compared to the baseline levels
 Assess statin tolerance and compliance
 In the case of significant statin intolerance and/or failure to
reach target levels, refer to lipid specialist (consider ezete-
mibe and PCSK9 inhibitors)
 Other
 Check for adherence to antithrombotic drugs
 Check renal function (urea, creatinine, electrolytes, esti-
mated glomerular filtration rate)
 Record body mass index, advise optimal body weight
 Re-enforce the importance of regular physical exercise
Symptoms and physical signs related to the revascularisation site
(and contralateral if applicable)
Other cardiovascular conditions
 Assess for cardiovascular symptoms
 Full clinical cardiovascular examination (including 12-lead ECG)
 Screening for AAA
AAA: abdominal aortic aneurysm; PCSK9: proprotein convertase subti-
lisin/kexin 9.
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stenosis greater than 70% or occlusion after carotid
endarterectomy (CEA) was 5.8% (95% conﬁdence
interval (CI) 4.1–8.2).16 In seven RCTs involving 2810
patients and over a mean of 37 months of surveillance,
5.2% CEA patients with a restenosis greater than 70%
or occlusion had a late ipsilateral stroke compared with
1.5% in patients without restenosis (odds ratio (OR)
4.77, 95% CI 2.29–9.92, P< 0.0001).16 In a secondary
analysis of the CREST study, female sex, diabetes, dys-
lipidaemia and continuing smoking were independent
predictors of restenosis after CEA.15
Carotid artery stenting. After carotid artery stenting
(CAS), most restenoses occur in the ﬁrst year. The
rate of recurrent cerebral ischaemic events is not signiﬁ-
cantly higher in patients with in-stent restenosis than in
those without.17
A meta-analysis of ﬁve RCTs observed that the preva-
lence of stenosis greater than 70% (or occlusion) in
patients undergoing CAS was 10.0% (95% CI 6.0–16.3)
over a mean follow-up of 62 months.16 In the EVA-3S
study, the 3-year rate of restenosis (50%) after CASwas
12.5%,17 with most restenoses occurring at 12 months or
later. However, most of these restenotic lesions were
moderate and severe lesions were infrequent. Female
gender, diabetes, and dyslipidaemia (but not smoking)
were independent predictors of restenosis. The rate of
late ipsilateral stroke in CAS patients with asymptomatic
untreated restenosis greater than 70% is very low (0.8%
over 50 months). In fact, 97% of those strokes occur in
patients without signiﬁcant restenosis or occlusion.16
Recurrence or development of atherosclerotic lesions.
Contralateral lesions are more common than ipsilateral
restenosis as their progression depends on the severity of
the disease at the time of intervention. In EVA-3S, most
patients with restenosis after CAS had recurrent stenosis
instead of residual stenosis.17 The rate of contralateral
greater than 70% restenosis or occlusion was 19.8% in
the CAS group and 18.5% in the CEA group. In a
cohort of 1639 patients, a 50–69% internal carotid
artery (ICA) stenosis observed in 282 patients progressed
to severe 70–99% stenosis in 32 patients (11.3%) during
a mean time of 30.7 26.5 months.18
Whether serial DUS surveillance confers any beneﬁt
remains controversial. DUS surveillance enables
monitoring of disease progression in the ipsilateral
and contralateral carotid arteries. Patients with greater
than 50% contralateral stenoses have been reported to
be ﬁve times more likely to progress during follow-up.
In some series, progression of the contralateral stenosis
has been associated with an increased risk of transient
ischaemic attack/stroke. In other series no stroke was
associated with a severe (>70%) contralateral ICA
stenosis.19
Long-term surveillance methods
Surveillance for restenosis after endarterectomy and
stenting relies mostly on DUS and particularly on the
peak systolic velocity (PSV), the systolic carotid vel-
ocity ratio and the end-diastolic velocity.20, 21 Each
DUS laboratory should validate its own criteria.
Following intervention (CEA or CAS), due to struc-
tural modiﬁcations of the arterial wall, it has been pro-
posed that DUS criteria for measuring restenosis
severity should be adapted.
After CAS, increased arterial stiﬀness and reduced
compliance of the ICA has haemodynamic conse-
quences. DUS velocity criteria for diagnosing greater
than 70% in-stent restenosis is higher than after CEA
(Table 2).22,23
In the case of an inconclusive study with DUS, CTA
is preferred as an alternative. MRA is not an option for
surveillance after CAS due to stent-related metal
artifacts.
Management of restenosis
In the absence of speciﬁc RCTs, symptomatic reste-
noses should be treated as soon as possible according
to the usual recommendations regarding ICA stenosis.7
The management of asymptomatic restenoses
remains highly controversial. In a recent meta-analysis
by Kumar et al.,16 the risk of late ipsilateral stroke in
patients with an asymptomatic 70–99% restenosis after
CAS was less than 1% at 4 years. Accordingly, any
reintervention would be unlikely to confer any signiﬁ-
cant long-term beneﬁt.
In contrast, the presence of an asymptomatic greater
than 70% restenosis after CEA was associated with a
small but signiﬁcant increase in the risk of late ipsilateral
stroke (about 3.7% increase in absolute risk over 3 years).
Consequently, for redo CEA or CAS to confer any long-
term beneﬁt (in terms of late stroke prevention), the pro-
cedural death/stroke rate should not exceed 1%.
However, an important patient subgroup to consider
for serial surveillance and reintervention would include
CEA and CAS patients who had a signiﬁcant decrease in
cerebral blood ﬂow during the procedure.7 This might
include CEA patients who developed neurological symp-
toms, coma or seizures during carotid clamping under
local anaesthesia, or similar symptoms during a CAS pro-
cedure. Another subgroup includes CEA patients who
developed signiﬁcant electroencephalographic changes
and/or a drop in mean middle cerebral artery velocities
to less than 15 cm/second during clamping under general
anaesthesia. These patients would be likely to have a
stroke in the case of restenosis progression.7
In light of the ongoing controversy, in patients with
an asymptomatic greater than 70% restenosis after
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CEA, decisions regarding whether redo CEA or CAS
might be appropriate should involve multidisciplinary
team input.
Mid and long-term surveillance protocol
Most RCT protocols for surveillance after CEA or CAS
have involved DUS studies at 1, 3, 6 and 12 months and
then yearly thereafter. Given the low incidence of resten-
osis and the very low risk of late ipsilateral stroke in
patients with a restenosis after CEA or CAS, the overall
beneﬁt of routine DUS surveillance remains question-
able. However, subgroups of patients might carry an
increased risk of restenosis, particularly women, patients
with diabetes and those with unfavourable control of
their risk factors. DUS also enables surveillance of dis-
ease progression in the contralateral carotid artery.7 In
conclusion, although it may remain controversial, given
a favourable beneﬁt/risk ratio, carotid DUS surveillance
at 1, 6, 12 and 24 months is reasonable. Beyond the
initial 2 years after revascularisation, and in the absence
of restenosis over the ﬁrst 2 years and any signiﬁcant
contralateral lesion an annual cardiovascular check-up
remains suitable, but DUS surveillance is not necessarily
needed (Figure 1).
Upper extremity artery disease
Mid and long-term outcome after revascularisation
The incidence of main mid and long-term (restenosis
or reocclusion) after revascularisation of upper extrem-
ity artery disease is comparable for both modalities:
primary patency rates of 93% at 2 years and 83–85%
at 5 years have been reported for endovascular
treatment (EVT)24, 25 versus 96% at 54 months for sur-
gical subclavian–carotid transposition.26 Extra-anato-
mical bypass surgery (mostly carotid–subclavian
bypass) has shown a secondary patency of 97% after
5 years.27
Table 2. DUS criteria for restenosis after revascularisation of various arterial territories.
PSV (cm/s) PSV ratio Reference
Carotid artery, stenosis after CEA
>50% 210–220 >2.25 AbuRahma et al., 200974, Aburahma, 201175
>70-80% 270–280 >3.35 AbuRahma et al., 200974, AbuRahma, 201175
Carotid artery, in stent stenosis after CAS
>50% >220 Lal et al., 200822, Stanziale et al., 200523
>70% 300 >4 Lal et al., 200822, Stanziale et al., 200523,
Zhou et al., 200876
Mesenterial artery, in stent stenosis
SMA 50% >325 3.5* AbuRahma et al., 201230
Celiac trunk 50% >270 3.5* AbuRahma et al., 201230
SMA 70% 400–445 8.45* AbuRahma et al., 201230, Soult et al., 201677
Celiac trunk 70% 290–360 5.75* AbuRahma et al., 201230, Soult et al., 201677
Renal artery, in stent stenosis**
Excludes >60% in stent stenosis <240 Del Conde et al., 201478
Intermediate zone 240–300 Del Conde et al., 201478
In stent stenosis (Specificity 94%) 300 Del Conde et al., 201478
>50% >200–350 >4.1* Scha¨berle et al., 201637
>60% >250 Fleming et al., 201038, Boateng et al., 201336
70% 395 5.1* Chi et al., 200979
Lower extremity, in stent stenosis
>50% 190 1.5 Baril et al., 200973
>70% 200–250 >2.0 Baril et al., 200973
80% 275 >3.5 Baril et al., 200973
Lower extremity, stenosis of vein bypass graft
>50% 180–300 2-3.5 Tinder et al., 200869
>70-80% 300 >3-3.5 Tinder et al., 200869
*Systolic ratio: target artery compared to PSV in aorta
**Cut-offs for renal ISR are still controversial and should be validated in individual laboratories (Del Conde et al., 2009). Higher values of PSV and
changes from baseline PSV increase specificity.
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Signiﬁcant risk factors for restenosis are age, smok-
ing, small stent diameter, implantation of two or more
stents, inﬂammation (e.g. high sensitivity C-reactive
protein level, leucocytosis) and concurrent carotid or
vertebral disease.28
Mid and long-term surveillance protocol
As subclavian artery stenosis is an acknowledged
marker of cardiovascular mortality, these patients
need the best medical treatment with a strict control
of cardiovascular risk factors (Table 1).3 Physical
examination including bilateral upper extremity blood
pressure (BP) measurement is recommended at 3, 6 and
12 months, and annually thereafter. If a restenosis is
suspected, DUS is indicated. After stenting or bypass,
DUS surveillance protocols are still debated and vary in
diﬀerent centres. In speciﬁc cases such as ipsilateral or
contralateral haemodialysis arteriovenous ﬁstula, cor-
onary artery bypass with the ipsilateral internal mam-
mary artery and bilateral subclavian artery stenosis,
serial DUS surveillance may be beneﬁcial. In these
cases, it is advisable to perform DUS surveillance at
1, 6 and 12 months, and annually thereafter (Figure 2).
Mesenteric artery disease
Imaging follow-up after treatment of acute or chronic
mesenteric artery disease is only needed if the patient
beneﬁts from an early diagnosis of a restenosis or occlu-
sion before symptoms develop.29 In the case of acute
embolic mesenteric ischaemia, appropriate care should
prevent new embolism, by treating the cause and/or pre-
scribing anticoagulants. If the ﬁrst acute event was due
to atherosclerosis, further bowel loss due to recurrent
mesenteric occlusion might be life threatening. This sup-
ports imaging follow-up in patients who had a mesen-
teric artery stenting or surgical procedure after acute
mesenteric ischaemia.30 We recommend DUS every 3
months during the ﬁrst year, and then yearly, in line
with previous reports.29,31,32 In the case of recurrent clin-
ical symptoms, CT is appropriate.
The follow-up strategy is very diﬀerent after the
treatment of chronic mesenteric ischaemia (CMI).
Most patients will develop symptoms of CMI (post-
prandial pain, weight loss, and/or diarrhoea) prior to
life-threatening bowel ischaemia. Thus, there is little
evidence that routine imaging follow-up after interven-
tion for CMI results in patient beneﬁt.29 However,
1(–3) mo
Clinical exam
Blood pressure
auscultation
Imaging
DUS
Biology
S-lipids
(3–)6 mo 1 year (Annually)
Figure 2. Surveillance recommendation after subclavian artery stenting or bypass. Physical examination including cervical and sub-
clavian auscultation, and bilateral upper extremity BP measurement is recommended at 3, 6 and 12 months, and annually thereafter. In
specific cases (see text), serial duplex ultrasound (DUS) surveillance may be beneficial. In these cases, we advise DUS surveillance at 1,
6 and 12 months, and annually thereafter. If there is a suspicion of restenosis with severe symptoms, DUS is indicated at 6 months, and
annual DUS may be beneficial in the following indications: haemodialysis fistula, arteria mammaria coronary artery bypass grafting and
subclavian steal syndrome.
1(–3) mo
Imaging
DUS
Biology
S-lipids
*If no progression at 2 year, or significant contralateral stenosis,
annual DUS not indicatedClinical exam
6 mo 1 year (Annually)
*
Figure 1. Surveillance recommendation after carotid endarterectomy and carotid artery stenting. Although it may remain contro-
versial, given a favourable benefit/risk ratio, duplex ultrasound (DUS) surveillance at 1, 6 and 12 months then yearly is reasonable until
new data are available. Beyond the initial 2 years after revascularisation, and in the absence of restenosis over the first 2 years and any
significant contralateral lesion, a less frequent DUS follow-up (e.g. every 2–3 years) can be considered, but an annual appointment with
a cardiovascular specialist remains suitable.
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clinical follow-up to secure best medical treatment and
to enable the patient to report symptom recurrence is
highly recommended (Figure 3).
Renal artery disease
Mid and long-term outcome
In atherosclerotic renal stenosis, a history of cardiovas-
cular disease (hazard ratio (HR) 2.84) and a 90% or
greater stenosis (HR 3.95) are independent predictors
of restenosis.33
Fibromuscular dysplasia is also an independent
factor of restenosis after endovascular angioplasty
(HR 2.65). In these patients, primary and assisted pri-
mary patency is 95%, 71% and 50%, and 100%, 100%
and 100% at 1, 5 and 9 years, respectively. Most of the
restenoses occur within the ﬁrst 6 months.34
Mid and long-term surveillance protocol
The follow-up of patients after renal revascularisation
depends on the cause of the initial renal artery stenosis.
It should be kept in mind that the course of hyperten-
sion (i.e. its cure and/or recurrence) is not always
related to renal restenosis, although it will always be
a signal requiring renal imaging.
Atherosclerotic renal artery stenosis. While the incidence of
restenosis after revascularisation is not well known,
restenosis may be inﬂuenced by the treatment modality
(e.g. angioplasty with or without stenting, surgical
repair).35
Surveillance after endovascular intervention, usually
stenting, is based on BP, renal function and DUS.36–38
Currently, no speciﬁc protocol has demonstrated any
superiority over others. Home-based BP surveillance
and renal function assessment every 3 months during
the ﬁrst year after stenting and every 6 or 12 months
thereafter are recommended. Furthermore, baseline
post-procedure DUS 1–3 months after stenting is rec-
ommended (Figure 4). Thereafter the imaging follow-
up should be clinically driven (changes in kidney func-
tion, BP control, antihypertensive therapy requirements
or occurrence of heart failure). If a restenosis is sus-
pected, DUS should be performed as the ﬁrst imaging
option to assess renal arteries and kidneys. The criteria
of in-stent restenosis (ISR) are presented in Table 2.
Changes from baseline post-stenting PSV add
sensitivity.
If the diagnosis byDUS remains doubtful and clinical
suspicion is strong, an angiogram with pressure gradient
measurement is recommended. CTA demonstrates a
high accuracy for detecting restenosis, but should be
limited to inconclusive DUS and/or preoperatively, in
order to avoid renal damage.37 Due to stent-related
metal artifacts, renal MRA is often suboptimal.
A similar follow-up protocol is recommended for
surgical repair.
Although the optimal treatment of restenosis is still
debated,39 there is a trend favouring the repetition of
the initial EVT, or bypass surgery following two fail-
ures. The ﬁnal decision should be guided by a consen-
sus between nephrologists, interventionists and
vascular surgeons.37
Fibromuscular dysplasia. The optimal post-revascularisa-
tion surveillance protocol is not well evidenced. DUS
is recommended at 1–3 months, every 6 months for the
ﬁrst 24 months and then annually (Figure 4). BP and
plasma creatinine levels must be carefully followed after
the ﬁrst month, and then every 3 months during the
ﬁrst year and twice a year thereafter. After a successful
revascularisation, antihypertensive medication will
probably need to be reduced or stopped, at least tem-
porally. As restenosis mostly occurs within the ﬁrst
6 months, DUS will be performed earlier in the case
of BP and/or plasma creatinine elevation.3,40 CTA or
1(–3) mo
Clinical exam
Acute embolic
Chronic
Acute on
chronic
9 mo6 mo 1 year (Annually)
Imaging
DUS
Biology
S-lipids
Figure 3. Surveillance recommendation after mesenteric artery stenting or bypass. In the case of embolic acute mesenteric
ischaemia, appropriate care should prevent a new embolism, by treating the cause and/or prescribing anticoagulants. If the acute event
was due to atherosclerosis (acute on chronic), trimestrial duplex ultrasound (DUS) during the first year and then annually is rec-
ommended. There is little evidence that routine imaging follow-up after intervention for chronic mesenteric ischaemia results in
patient benefit. Annual clinical follow-up is recommended to secure best medical treatment, including smoking cessation, and to enable
the patient to report symptom recurrence.
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MRA are not recommended for routine surveillance in
the absence of untreated aneurysms.
Any signiﬁcant restenosis should lead to angiography
and angioplasty. CTA orMRAmight be needed to con-
ﬁrm the DUS diagnosis and better assess potential tech-
nical issues. Surgery should be considered in the case of
complex lesions or recurrent stenosis.
Lower extremity artery disease
The revascularisation indications in LEAD relate pri-
marily to chronic limb-threatening ischaemia (CLTI),
and severe, disabling claudication, especially if medical
management and exercise therapy are ineﬀective.
Follow-up may diﬀer according to the indication for
revascularisation, the type of revascularisation and
the patient’s physical condition. The aim of surveillance
is to prevent revascularisation failure and eventually
amputation. The surveillance should not only focus
on the revascularisation site, but must include the com-
pletely revascularised limb as well as the contralateral
limb, along with a general clinical cardiovascular sur-
veillance (Table 1).
Mid and long-term outcome
After surgery. The ﬁrst-year incidence of vein graft sten-
osis is 20%.41,42 During the ﬁrst 3 months, bypass sten-
osis/thrombosis can be due to technical issues. Almost
15% of graft failures occur during the ﬁrst month;
almost 80% during the ﬁrst 2 years and no more than
5% thereafter.43, 44 During the mid-term period, bypass
failure is predominantly associated with intimal hyper-
plasia causing anastomotic stenosis, graft stenosis or
occasionally with ﬁbrosis of the valve cusp. These are
the most common causes of potentially identiﬁable and
treatable graft stenoses.
The majority of signiﬁcant graft stenoses are asymp-
tomatic and only 11–38% can be diagnosed by ischae-
mic symptoms or decreased pulse on physical
examination.45,46 ABI drop greater than 0.15 has been
proposed to detect revascularisation failure, but its sen-
sitivity is poor. Hence, the use of ABI alone to monitor
a revascularised limb should be avoided, and it should
always be used in combination with DUS.47 In patients
with abnormal DUS and ABI the reported graft failure
is 66% in the 3-month period following measure-
ments.48 Angiography (CTA, MRA or digital subtrac-
tion angiography) is proposed only if there are clinical
and/or ultrasound data suggesting graft failure or dis-
ease progression.
Signiﬁcant (>50%) vein graft or anastomosis ste-
noses are usually treated by EVT. Studies comparing
endovascular techniques are scarce.49 In the case of
multiple restenosis, surgical revision and replacement
of the diseased segment with a vein interposition or a
jump graft/patch angioplasty in the anastomotic sten-
osis is recommended. In the case of vein graft occlusion,
thrombolysis should be performed within 6–48 hours
after symptom onset with treatment of the defect, but
re-thrombosis is not rare even though the underlying
cause has been corrected. For prosthetic bypasses
(polytetraﬂuoroethylene, dacron), thrombolysis can
usually be eﬀective up to 2 weeks. The intra-arterial
catheter for thrombolysis is usually introduced inside
the graft by the contralateral groin. Low dose alteplase
(1mg/hour) for 12–48 hours is a commonly used
protocol.
After EVT for vein graft stenosis, a 1–6-month dual
antiplatelet therapy with aspirin and clopidogrel is usu-
ally prescribed unless the patient has an increased
bleeding risk.3
After revascularisation following vein graft occlu-
sion, anticoagulants (usually low molecular weight
FMD
Atherosclerotic
RAS or bypass
Clinical exam
Blood pressure measurement
(home based after RAS due to
PAD)
Imaging
DUS
Biology
S-creatinine, eGFR *After revascularization of FMD, twice a year
1(–3) mo 9 mo 18 mo6 mo 1 year (Annually)
**
Figure 4. Surveillance recommendation after renal artery stenting or bypass. Fibromuscular dysplasia (FMD): Currently the optimal
post-revascularisation monitoring protocol is not well evidenced. We propose a duplex ultrasound (DUS) at baseline, every 6 months
for the first 24 months and then annually. Blood pressure (BP) and plasma creatinine levels must be carefully followed with a first
control one month after revascularisation, every 3 months during the first year and twice a year thereafter. Atherosclerotic lesions:
We recommend a home-based BP surveillance and renal function testing every 3 months during the first year after stenting and every
6–12 months thereafter. Furthermore, baseline post-procedure and DUS 1–3 months after stenting or surgical repair is recom-
mended. Thereafter the imaging follow-up should be clinically driven (changes in kidney function, BP control, antihypertensive therapy
requirement or heart failure). If there is a suspicion of restenosis in BP or renal function testing, DUS is recommended.
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heparin) are combined with antiplatelet therapy
(aspirin or clopidogrel). The duration of the anticoagu-
lation varies between one month and lifelong and
should be tailored according to the cause of the graft
occlusion, to previous thrombotic events (particularly
previous graft occlusions) and to the patient’s bleeding
risk. In long-term anticoagulation treatment, vitamin K
antagonists are used.
After prosthetic bypass occlusion, long-term antic-
oagulation therapy should be considered.50
Considering the lack of data on direct oral anticoagu-
lant use for this indication, long-term vitamin K antag-
onists are usually recommended.
If the autologous vein bypass graft has been
uneventful for 12 months, late issues are scarce. After
the ﬁrst postoperative year, the annual incidence of
autologous graft failure is estimated to be approxi-
mately 1–2%.51,52 After venous bypass surgery, 5-year
follow-up has shown LEAD progression in 19% of
cases.53 For prosthetic grafts, late occlusion rates are
higher, as 40% of femoropopliteal prosthetic grafts are
expected to occlude within 5 years.54 Anastomotic
pseudoaneurysms are rare.
Theprogressionofatherosclerosis canbe seen either in
the inﬂow or outﬂow vessels. Prosthetic grafts may show
late anastomosis stenoses. In the case of severe progres-
sion of atherosclerosis in the inﬂow or outﬂow arteries,
typical symptoms of LEAD (claudication, rest pain,
tissue lesion) or graft occlusion may occur. However, in
many cases disease progression can be asymptomatic.
Typically, these patients showupwhenLEADsymptoms
appear. Imaging is indicated irrespective of symptoms. If
bypass patency is threatened, intervention is usually rec-
ommended even if clinical symptoms aremild, according
to the multidisciplinary team assessment.
After EVT. The most common mid-term complications
after EVT are restenosis and occlusion of the treated
vessel segment, ranging from approximately 5% in
the pelvic region up to over 50% in the
infrapopliteal arteries. Recurrence of symptoms may
also be due to disease progression above or below the
angioplasty site.55
Restenosis is mainly related to intimal hyperplasia at
the balloon dilation site and at the proximal or distal
end of the stent. Restenosis can also be related to initial
suboptimal procedural results (residual dissection,
>50% residual stenosis, distal embolisation, acute
recoil, or inadequate inﬂow or outﬂow treatment).56,57
Restenosis/occlusion can be asymptomatic or can cause
typical symptoms (claudication, recurrence of leg pain
and/or non-healing lesions) requiring reintervention.
Pulse palpation and ABI in combination with DUS
are used for follow-up (Figure 5). In the case of recur-
rent claudication, the treadmill test with post-exercise
ABI can assess the functional severity.3 Stent throm-
bosis usually presents with acute worsening of symp-
toms and sometimes acute limb ischaemia.
Endovascular reintervention is the ﬁrst-line treat-
ment option in clinically relevant restenosis or occlu-
sion. If EVT is not successful, bypass surgery might be
considered. After a second failure of EVT, a multidis-
ciplinary vascular team should evaluate the patient.3
After endovascular reintervention, dual antiplatelet
therapy with aspirin and clopidogrel should be
considered for a longer period than after the ﬁrst inter-
vention, taking into account the patient’s bleeding risk
and the lesion location, with shorter duration in prox-
imal versus distal lesions. A period of at least 3 months
is recommended. However, due to the lack of evidence
for these recommendations, this is based on clinical
experience and expert opinion.
The long-term natural history of LEAD following
EVT has been poorly investigated. Unlike surgery, no
plateau phase is seen in the incidence of EVT failure
after the ﬁrst months, but there is a relatively constant
IC (1)
CLTI (2)
1(-3) mo
Clinical exam, blood pressure, ABI+TP, In
CLTI: WIFI-classification TcPO2 if needed
Imaging
DUS up to 24 mo
Biology
S-lipids *DUS recommended up to 2 year after bypass
6 mo 1 year (Annually)
*
*
*
*
Figure 5. Surveillance recommendation after vein bypass for lower extremity artery disease. Surveillance includes clinical exam-
ination, ankle brachial index (ABI) (or toe pressure/toe brachial index (TBI)) measurement and duplex ultrasound (DUS). Although
solid scientific evidence is lacking, there is consensus that the first post-discharge test should be performed within 4–6 weeks,
thereafter at 3 months, 6 months, 12 and 24 months after bypass surgery. If a new intervention is performed for graft stenosis or
occlusion, the surveillance programme is re-initiated from the start. Clinical surveillance is lifelong and of paramount importance
especially for patients with chronic limb-threatening ischaemia (CLTI) (see Table 1). If there is a suspicion of restenosis, an angiogram is
recommended.
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failure rate for at least the ﬁrst 5 years. The failure rate
is quite low for iliac arteries, but deﬁnitely higher
for femoropopliteal and for below the knee arteries
(Figure 6).
Severe restenosis accounts for the majority of rein-
terventions; because restenosis is usually symptomatic,
the role of DUS surveillance in guiding reinterventions
is questionable.58
Beyond one year, the reported incidence of late stent
thrombosis is 10% at a median follow-up of 19 months
in the femoropopliteal segment.58 It is not always pre-
ceded by severe in-stent restenosis, making this compli-
cation unpredictable by means of DUS surveillance.
After iliac stenting, the reported reintervention rate
at 5 years is as low as 2.5% for primary stenotic lesions
and 12.5% for primary occlusions, with a 6-year pri-
mary patency rate of 82.4% and 77.7%, respectively.59
In the femoropopliteal segment, most studies reporting
long-term data include only patients with Trans-
Atlantic Consensus (TASC) A and B lesions. In this
setting, the average 5-year freedom from target lesion
revascularisation has been reported to be approxi-
mately 70–80%.60
Very few studies describe long-term results after
infrapopliteal EVT; 5-year primary patency ranges
from 38% in one study on balloon angioplasty,61 to
9% with bare metal stents and 12% with drug-eluting
stents in another trial.62 Importantly, 5-year freedom
from major amputation (range 66–81%) was deﬁnitely
higher than primary patency in both trials.
Late complications are usually suspected by the
reoccurrence of symptoms. DUS is the mainstay for
the diagnosis and guidance of treatment. Restenosis
after EVT is usually amenable to repeat balloon angio-
plasty with or without stenting or to bypass in the case
of repeated failure. Acute thrombosis can be treated by
aspiration and/or thrombolysis, but revascularisation
by EVT is much more diﬃcult if the thrombosis
is old. Reintervention should be decided on a case-
by-case basis, taking into account the severity of
symptoms, the general condition of the patient (renal
function, bleeding risk) and the likelihood of success
(history of recurrent restenosis) preferably by the multi-
disciplinary team.
Disease progression. Atherosclerosis involves the whole
vascular tree and coexisting atherosclerotic manifest-
ations in other vascular beds are very common in
patients with LEAD.3 Patients with multisite artery dis-
ease more often have progressive atherosclerosis in all
vascular beds and have a higher incidence of cardiovas-
cular events.63,64 Therefore, it is of paramount import-
ance to prevent atherosclerosis progression by regularly
monitoring risk factor modiﬁcation, exercise training
and medical therapy.
In patients with intermittent claudication, disease
progression to CLTI may be underestimated. In a
meta-analysis of studies conducted between 1990 and
2015, 21% of patients with intermittent claudication
were diagnosed with CLTI during a 5-year follow-up
period and 4–27% of them had amputations.55 On the
other hand, a recent RCT on EVT for femoropopliteal
disease showed a rate of persistent or worsening clau-
dication or CLTI at 5 years of 20% in the DES arm and
of 41% in the balloon angioplasty with or without bare
metal stent arm.60 Therefore, the regular follow-up pro-
gramme should involve assessment for atherosclerosis
in both lower limbs and clinical manifestations of other
clinical sites such as coronary arteries, carotid arteries
and the abdominal aorta.
IC (1)
CLTI (2)
1(–3) mo
Clinical exam, blood pressure, ABI+TP, In
CLTI: WIFI-classification,TcPO2 if needed
Imaging
DUS
Biology
S-lipids
• DUS should be repeated after discharge only in case of symptom
   recurrence
(3–)6 mo 1 year (Annually)
*
Figure 6. Surveillance recommendation after endovascular treatment (EVT) for lower extremity artery disease (LEAD). Surveillance
includes clinical assessment looking for recurrent symptoms or signs, ankle brachial index (ABI) measurement and duplex ultrasound
(DUS). Further tests such as toe pressure and/or transcutaneous oxygen tension (TcPO2) may be needed in the case of chronic limb-
threatening ischaemia (CLTI). DUS surveillance after EVT by means of an initial test performed between discharge and one month is
recommended; if results are normal, subsequent examinations should be performed at 6 and 12 months; while if the initial DUS is
abnormal, reintervention or closer DUS follow-up should be decided on a case-by-case basis. The usefulness of a yearly DUS beyond
12 months in revascularised patients who remain asymptomatic has never been proved, and cannot be recommended as routine
surveillance; however, these patients require a comprehensive cardiovascular surveillance focused on risk factor management, exercise
training and medical therapy on a yearly basis. Clinical surveillance is lifelong and of paramount importance especially for patients with
CLTI (Table 1). If there is a suspicion of restenosis which requires treatment, an angiogram is recommended.
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Mid and long-term surveillance protocol
After bypass surgery. Graft failure should be identiﬁed
before occlusion occurs. Not all graft stenoses progress
to occlusion: in a study of 63 duplex-veriﬁed stenosis
with over 50% of diameter reduction, 43% resulted in
bypass thrombosis during the following 8 months.65
Low ﬂow is also reported as an indicator of an
increased risk of graft failure.66
Surveillance includes clinical examination, ABI (or
TBI) measurement and DUS. Optimally, detailed
description of the procedure and previous DUS exam-
inations should be available for the sonographer. In a
meta-analysis of 15 RCTs, DUS surveillance after
venous bypass surgery did not improve graft patency
and was associated with a statistically non-signiﬁcant
decrease in the amputation rate (OR 0.7, 95% CI
0.23–2.13).67 In another retrospective analysis on 1404
bypass patients scheduled for routine DUS surveil-
lance, 200 (14%) patients sustained graft occlusion. In
a multivariate analysis, non-adherence to a DUS sur-
veillance programme was independently associated
with venous graft occlusion (HR 1.58, 95% CI 1.10–
2.27).68 This cannot only be due to DUS surveillance
but also to treatment adherence and accurate clinical
follow-up, emphasising the importance of long-term
medical management of these patients beyond imaging.
In the lack of solid evidence, there is a consensus that
the ﬁrst post-discharge test should be performed within
4–6 weeks, thereafter at 3 months, 6 months, 12 and 24
months after bypass surgery. If a reintervention is per-
formed for graft stenosis or occlusion, the surveillance
programme should be reinitiated from the start.
Although DUS surveillance may stop after 24 months,
clinical surveillance is lifelong and of paramount import-
ance especially forpatientswithCLTI (Figure5,Table1).
Some features are considered as high risk for graft
thrombosis and requiring closer attention: spliced
grafts, poor quality vein (varicose lesions, vein with a
thick wall, post-thrombotic manifestations, vein diam-
eter <3mm), poor run-oﬀ or secondary bypass sur-
gery.69,70 Also, an abnormal DUS scan at 4–8 weeks
has been predictive of later graft failure. McBride
et al.70 proposed a decision tree to identify high-risk
grafts for DUS surveillance. In the surveillance of 249
bypass grafts the sensitivity and speciﬁcity of their
model for the prediction of graft stenosis occlusion
were 95% and 52%, respectively; the negative predict-
ive value being 97%.66
After EVT. Surveillance includes clinical assessment look-
ing for recurrent symptoms or signs, ABI (or TBI) meas-
urement and DUS. Although ABI adds signiﬁcant
information to clinical examination, it correlates
poorly with angiographic stenosis, and a signiﬁcant
decrease in ABI (>0.15) may not be present until a
greater than 60% stenosis exists. However, it may be
useful to perform ABI measurements within one
month of EVT, at 6 and 12 months. Duplex scan is
more sensitive to detect restenosis, but to date there is
no clear evidence showing that DUS surveillance
improves limb outcomes. Initial studies indicated that
an abnormal ﬁrst DUS (1–30 days after EVT) was asso-
ciated with higher target lesion revascularisation at one
year.71,72 More recently, DUS surveillance has been
reported to predict severe in-stent restenosis with a spe-
ciﬁcity greater than 90%.73 However, a DUS-based sur-
veillance protocol at 3, 6 and 12 months after superﬁcial
femoral artery (SFA) or popliteal angioplasty with or
without stenting reported a sensitivity and a speciﬁcity
of 88%and 60%, respectively, to predict complete occlu-
sion with 2 years of follow-up.58 About half of severe
restenoses present with ischaemic symptoms requiring
reintervention, regardless of DUS ﬁndings. Whether
identifying asymptomatic severe restenoses should lead
to immediate reintervention or closer follow-up is uncer-
tain. If restenosis requiring treatment is suspected in
DUS, a digital subtraction angiogram is recommended
and re-EVT if possible at the same session.
In conclusion, based on consensus rather than strong
evidence, we recommend DUS surveillance after EVT
by means of an initial test performed between discharge
and one month; if the results are normal, DUS is rec-
ommended if symptoms reappear. However, if the ini-
tial DUS is abnormal, reintervention or closer DUS
follow-up should be discussed on a case-by-case basis.
The usefulness of a yearly DUS beyond 12 months in
revascularised patients who remain asymptomatic has
never been proved, and cannot be recommended as
routine surveillance. These patients require a compre-
hensive cardiovascular surveillance focused on risk
factor management, exercise training and medical ther-
apy on a yearly basis.
Special aspects after revascularisation for CLTI
After revascularisation for CLTI, closer follow-up and
wound care is recommended until wounds are healed,
and 30-day, 3–6 and 12-month surveillance is recom-
mended. After wound healing, annual appointments
with vascular physicians/surgeons should be organised
to check for symptoms, foot condition, ABI, cardiovas-
cular risk factors as well as availability to check toe
pressures and transcutaneous oxygen tension (TcPO2)
if needed (Table 1).
Conclusion
This paper aims to provide a standardised follow-up
approach, based on a combination of evidence and
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authors’ expertise, emphasising the importance of a
multidisciplinary management of these patients with
an optimal, clinically reasonable and cost-eﬀective
strategy. This collaborative work highlights many
gaps in the evidence and suggests collaborative research
to provide further data and evidence in this setting.
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